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Background
Despite the succes story of therapeutic monoclonal anti-
bodies (mAbs), a medical need remains to improve their
efficacy. One possibility to achieve this is to modulate
important effector functions such as the antibody
dependent cellular cytotoxicity (ADCC). The advantage
of highly active biotherapeutic molecules is - apart from
the enhanced efficacy - the reduction of side effects due
to lower administered doses. Furthermore, these thera-
peutic antibodies may enable treatment of current non-
responders, e.g. patients with low antigen bearing
tumors. Enhancement of the effector functions of anti-
bodies can be achieved either by directly mutating the
antibody’s amino acid sequence or by modifying its gly-
cosylation pattern, e.g. by using a novel host cell line
able to attach a desired glycostructure to the product.
The latter approach has the advantage of not impacting
the antibody structure itself, thereby avoiding negative
effects on the PK/PD of the molecule. During the last
decade it has been shown that antibodies with a reduced
level of glycan fucosylation are much more potent in
mediating ADCC, a mode of action particularly relevant
for cancer therapeutics. Therefore, defucosylated antibo-
dies are of major interest for biotherapeutics developers.
To produce such antibodies, Boehringer Ingelheim has
inlicensed the GlymaxX® system from ProBioGen, Ger-
many. This technology utilises the bacterial protein
RMD (GDP-6-deoxy-D-lyxo-4-hexulose reductase)
which, when stably integrated into host cell lines, inhi-
bits fucose de-novo biosynthesis. The enzyme deflects
the fucosylation pathway by turning an intermediate
(GDP-4-Keto-6-Deoxymannose) into GDP-Rhamnose, a
sugar that cannot be metabolised by CHO cells. As a
consequence, recombinant antibodies generated by such
host cells exhibit reduced glycan fucosylation and 20-
100 fold higher ADCC activity. Here, we show the
establishment of a new host cell line, termed BI-HEX®-
GlymaxX® which is capable of producing highly active
therapeutic antibodies. We furthermore present data on
the cell line properties concerning cell culture perfor-
mance (e.g. titer, growth, transfection efficiency), process
robustness and product quality reproducibility.
Methods
The BI-HEX® host cell line was transfected with the
bacterial RMD enzyme and stably expressing clones
were selected. The presence of RMD was confirmed by
Western blotting. The clones were analysed for stability
of RMD expression over time in continous culture
(>100 days), glycoprofile structure, CD16 binding and
ADCC activity of mAbs produced by these clones before
selection of the final new BI-HEX®-GlymaxX® host cell.
Furthermore, we examined the growth and cultivation
properties of the modified BI-HEX®GlymaxX® cells to
ensure that the engineered host cell maintained the
favourable manufacturability properties of BI-HEX® and
we tested the reproducibility of key product quality
attributes of the generated antibodies.
Results
Up to date seven different antibodies were produced in
our new BI-HEX®-GlymaxX®host cell line. All molecules
showed a very significant reduction of fucosylation down
to 1-3% compared to the control. Correlating with the low
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exhibited a 20-100× increased ADCC activity (Figure 1A).
This enhancement also correlated well with an increase in
CD16 binding. For the routine cell line and process devel-
opment we investigated the robustness of the defucosyla-
tion and its resulting activity enhancement. The results
indicated a high reproducibility between independent pro-
duction runs. The ADCC level as well as the CD16 bind-
ing was robust for all analysed mAbs (Figure 1B).
Investigating the cell culture behaviour of the BI-HEX®-
GlymaxX®and its parental BI-HEX® cell line, we saw com-
parable results for their transfection efficiencies, doubling
times, titer and production run performance. Depletion
studies of RMD showed that this enzyme can be efficiently
depleted during downstream purification of the mAb.
Conclusions
Our new BI-HEX®-GlymaxX®cell line is capable of pro-
ducing >90% defucosylated antibodies which exhibit a
20-100 fold higher ADCC activity compared to a normal
CHO production cell line like BI-HEX®. This increase in
ADCC activity correlated with a stronger CD16 binding
in those molecules. Furthermore, the BI-HEX®-Gly-
maxX® cells show the same manufacturing properties
(transfection efficiency, doubling times, titer, peak cell
density) to its originator cell line. For the depletion of
RMD we’ve established a sensitive depletion assay and
measured a complete reduction of RMD after the first
purification step (protein A capture).
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Figure 1 A) Comparison of ADCC activity of Rituximab produced in either BI-HEX® or BI-HEX®-GlymaxX® . B) ADCC activity of 3 different
mAbs produced in BI-HEX®-GlymaxX® . Three independent production runs were performed for each mAb. The mAbs were individually purified
by protein A capture before ADCC activity determination.
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